Myra Vision's Calibreye aqueous shunt for glaucoma patients is designed to provide adjustable and reversible outflow control.

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...

Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by high pressure inside the eye. Patients often rely on daily eye drops to ...

For patients for whom surgery is indicated but who are opposed to undergoing glaucoma surgery, he may suggest a different ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...